Publications by authors named "C R Crawley"
Article Synopsis
- HLA mismatching (different types of immune cells) can make it harder for patients with blood cancer to survive after getting a transplant.
- In a study with over 17,000 patients, those with mismatched HLA types had lower survival rates, especially with certain HLA classes.
- Using a new treatment called post-transplantation cyclophosphamide (PTCy) helps reduce some risks, but HLA mismatching still leads to higher death rates in both PTCy and traditional transplant methods.
HLA-DP permissive mismatches can be assigned a direction according to their immunopeptidome divergence across core and noncore subsets. Noncore permissive graft-versus-host mismatches show significantly reduced risks of relapse without increased nonrelapse mortality compared with allele-matched pairs.
View Article and Find Full Text PDFBackground: Celiac disease (CeD) has an estimated prevalence of 1%-3%. The classical clinical presentation is malabsorption, but now patients may present with more subtle symptoms such as constipation, osteoporosis, or iron deficiency anemia. Children may also present with poor growth.
View Article and Find Full Text PDFThe objective of the study was the analysis of clinical types, outcomes, and risk factors associated with the outcome of adenovirus (ADV) infection, in children and adults after allo-HCT. A total number of 2529 patients (43.9% children; 56.
View Article and Find Full Text PDFSystemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials.
View Article and Find Full Text PDF